Diagnostics firm CardioDx Inc. raises $58 million in a private placement announced Aug. 27. The proceeds will support commercial expansion of the firm’s Corus CAD blood-based genomic test for assessing the potential for obstructive coronary artery disease, which launched in the U.S. in 2009. (See Also see "CardioDx Launches Gene Test For Obstructive Coronary Disease" - Medtech Insight, 7 September, 2009..)
A portion of the funds also will support development of additional genomic cardiovascular disease diagnostics, according to the company. Earlier...
Welcome to Medtech Insight
Create an account to read this article
Already a subscriber?